Can Mineralys Therapeutics (MLYS) Stock Reach $48?

Mineralys Therapeutics, Inc. (MLYS) is a clinical-stage biopharmaceutical company developing lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor for uncontrolled and resistant hypertension. With a Food and Drug Administration decision date approaching, the gap between the stock's current price and the average analyst price target is unusually wide, making the "Can MLYS reach $48?" question central to the bull-bear debate.

Key Takeaways

• The central stock price target of $48 is the arithmetic mean of eight attributable analyst targets reviewed, rounded to a clean level.
• The verified latest closing price of approximately $21.64 implies a required upside of roughly 122%, a very large move.
• Individual analyst targets span a wide $29 to $56 range, reflecting genuine disagreement about launch economics and competition.
• The strongest support is lorundrostat's positive pivotal data and an FDA PDUFA (Prescription Drug User Fee Act) decision date of December 22, 2026.
• The biggest risks are regulatory uncertainty, a missed Phase 2 sleep-apnea endpoint, and AstraZeneca's first-mover hypertension launch.

Analyst Price Targets and Consensus View

The $48 central target is derived from eight current, named price targets rather than any single firm's view: H.C. Wainwright ($56), Wells Fargo ($55), LifeSci Capital ($54), Guggenheim ($52), Stifel ($52), Bank of America ($49), Goldman Sachs ($40), and UBS ($29). The arithmetic mean is approximately $48.4, rounded to $48, with a low-to-high range of $29 to $56. Most firms rate the stock Buy or equivalent, but the range is wide for a reason.

Bullish analysts emphasize the scale of the unmet need — roughly 20 million U.S. adults with uncontrolled or resistant hypertension — and lorundrostat's meaningful systolic blood-pressure reductions across the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. More cautious targets, such as UBS's $29, weigh the competitive threat from AstraZeneca (AZN), whose aldosterone-synthase inhibitor reached the market first, and the commercial execution risk of a pre-revenue launch. Notably, Goldman Sachs trimmed its target from $42 to $40 in August 2026, illustrating how even supportive analysts are moderating expectations.

Current Market Position and Path Toward the Target

With shares near $21.64, reaching $48 requires roughly a 122% advance — a very large move that would essentially more than double the market capitalization. This is not a modest re-rating; it reflects the stock's sharp de-rating after trading in the mid-$40s in late 2025 before slipping through 2026.

The clearest path runs through the December 22, 2026 PDUFA decision. An approval, combined with a well-executed launch into a large, underserved hypertension population, would give the company its first commercial revenue and could justify a fundamentally higher valuation. The company ended the second quarter of 2026 with about $661.4 million in cash, cash equivalents, and investments and has stated its runway extends into 2028, reducing near-term dilution risk as it approaches commercialization.

What Could Support a Move Toward the Target

Several verified factors support the bull case. Lorundrostat has completed six late-stage trials, including the two registrational studies backing the New Drug Application, with statistically significant and durable blood-pressure reductions and a favorable safety profile. The company has repurchased its future royalty obligations to Mitsubishi Tanabe Pharma, a step management argues enhances long-term economics, and has built out its commercial and medical affairs organization ahead of the potential launch. A $500 million term loan facility and $150 million equity raise have strengthened the balance sheet.

What Could Prevent the Target From Being Reached

The risks are equally concrete. The FDA could delay or reject the application, and even an approval does not guarantee commercial success against AstraZeneca's earlier entrant, which already has label, pricing, and payer positioning. The Phase 2 Explore-OSA trial missed its primary endpoint on apnea-hypopnea index, narrowing the label-expansion story to hypertension and related comorbidities. The company is pre-revenue and posted a $241.1 million net loss in the second quarter, driven largely by the royalty repurchase, and its future depends almost entirely on a single asset.

Technical Levels and Market Structure

From a market-structure perspective, the stock is well below its late-2025 trading range in the mid-$40s, so a move toward $48 would first require reclaiming that prior area. The $29 and $40 marks also serve as useful reference points on the way, given they correspond to the cautious and mid-range analyst targets. In broad terms, the path to $48 would unfold in stages, each tied to regulatory or commercial news rather than momentum alone.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of about 12 months, though individual firms rarely disclose identical time frames. The pivotal near-term catalyst is the December 22, 2026 PDUFA decision. Investors should also monitor quarterly earnings and guidance, any label and pricing disclosures, payer coverage announcements, launch metrics such as prescriptions and sales-force productivity, and updates on competition from AstraZeneca. Analyst target revisions around approval will likely set the tone for the next leg of the stock forecast.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like MLYS, such tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how the system currently reads the setup.

Final Assessment

Reaching $48 would require Mineralys Therapeutics to more than double from its current price, a very large move that hinges almost entirely on the December PDUFA outcome and the subsequent commercial launch. The analyst-derived target of $48 sits well above even the cautious $29 low, and the wide $29–$56 range signals that even bullish analysts disagree sharply on execution and competition. Positive pivotal data, a fortified balance sheet, and a large addressable market support the case, while regulatory risk, a missed sleep-apnea endpoint, and AstraZeneca's first-mover advantage represent the principal obstacles. The stock forecast ultimately turns on whether lorundrostat gains approval and converts a large clinical opportunity into real commercial traction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations